HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Stanley John Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by John, S. Articles by Bashi, V. V. Search for Related Content PubMed PubMed Citation Articles by John, S. Articles by Bashi, V. V.

Ann Thorac Surg 2000;69:1167-1172
© 2000 The Society of Thoracic Surgeons

---

ORIGINAL ARTICLES: CARDIOVASCULAR

25-year experience with 456 combined mitral and aortic valve replacement for rheumatic heart disease

^a Department of Cardiothoracic Surgery, Christian Medical College Hospital, Vellore, India
^b Department of Cardiothoracic Surgery, Manipal Heart Foundation, Bangalore, India

Address reprint requests to Dr John, Yellamma Dasappa Hospital, 25 Andree Rd, Bangalore 560 027, India

Background. Valvular heart disease in developing countries resulting from rheumatic fever is disabling and if untreated leads to congestive heart failure and death. Valve replacement has remained the procedure of choice for advanced valve disease.

Methods. Between 1973 and 1997, 456 patients underwent combined mitral and aortic valve replacement. In light of our favorable earlier experience the Starr-Edwards ball valve prostheses were implanted in 90% and 72.8% of mitral and aortic positions, respectively. Follow-up ranged from 1 to 24 years with a median of 8.5 years.

Results. The 30-day hospital death rate was 9.2% and late death occurred in 10.1%. A low-intensity anticoagulant regimen was followed to maintain the target prothrombin time at 1.5 times the control value. The actuarial survival at 5, 10, 20, and 24 years was 90.4%, 85.6%, 84.4%, and 82.4% per year, respectively.

Conclusions. In view of the acknowledged advantage of superior durability, increased thromboresistance in our patient population, and its cost effectiveness the Starr-Edwards ball valve is the mechanical prosthesis of choice for advanced combined valvular disease. The low-intensity anticoagulant regimen has offered sufficient protection against thromboembolism as well as hemorrhage.

This article has been cited by other articles:

				R. P Akhtar, A. R Abid, H. Zafar, S. S Sheikh, M. A Cheema, and J. S Khan Prosthetic Valve Replacement in Adolescents with Rheumatic Heart Disease Asian Cardiovasc Thorac Ann, December 1, 2007; 15(6): 476 - 481. [Abstract] [Full Text] [PDF]

				R. Thankachen, B. George, V. Shukla, and R. J Korula Aortic and Mitral Valve Replacement in a Patient with Hemophilia B Asian Cardiovasc Thorac Ann, December 1, 2007; 15(6): 526 - 527. [Abstract] [Full Text] [PDF]

				J.-P. Remadi, O. Baron, C. Tribouilloy, J. C. Roussel, O. Al Habasch, P. Despins, J.-L. Michaud, and D. Duveau Bivalvular mechanical Mitral-Aortic valve replacement in 254 patients: Long-Term results--a 22-year follow-up Ann. Thorac. Surg., August 1, 2003; 76(2): 487 - 492. [Abstract] [Full Text] [PDF]

				H.-Y. Yu, Y.-L. Ho, S.-H. Chu, Y.-S. Chen, S.-S. Wang, and F.-Y. Lin Long-term evaluation of Carpentier-Edwards porcine bioprosthesis for rheumatic heart disease J. Thorac. Cardiovasc. Surg., July 1, 2003; 126(1): 80 - 89. [Abstract] [Full Text] [PDF]

				R. Higashita, S. Ichikawa, H. Niinami, T. Ban, Y. Suda, and Y. Takeuchi Long-term results after Starr-Edwards mitral valve replacement in children aged 5 years or younger Ann. Thorac. Surg., March 1, 2003; 75(3): 826 - 829. [Abstract] [Full Text] [PDF]